LH
Labcorp Holdings Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 88.13K | $17.42M | n/a | n/a |
| Q2 2026 | 158 | +5 | 56.54M | $15.82B | +9 | −3 |
| Q1 2026 | 155 | +1 | 55.32M | $14.74B | +4 | −4 |
| Q4 2025 | 153 | -1 | 61.82M | $15.50B | +1 | −1 |
| Q3 2025 | 19 | 0 | 33.10M | $9.50B | n/a | −1 |
| Q2 2025 | 17 | -1 | 30.31M | $7.95B | +1 | −2 |
| Q1 2025 | 15 | +2 | 7.94M | $1.85B | +2 | n/a |
| Q4 2024 | 13 | 0 | 9.58M | $2.20B | +2 | −2 |
| Q3 2024 | 12 | +1 | 4.32M | $962.67M | +2 | −1 |
| Q2 2024 | 11 | n/a | 5.93M | $1.21B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 2.23M | n/a | $453.25M | 0.1% | n/c | 1 | SEC ↗ ×7 |
| 2 | Geode Capital Management ✦ (passive) | 1.95M | n/a | $396.05M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passive) | 1.03M | n/a | $209.67M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | AQR Capital Management ✦ | 282.96K | n/a | $57.53M | 0.1% | n/c | 1 | SEC ↗ ×4 |
| 5 | Bridgewater Associates ✦ | 207.51K | n/a | $42.23M | 0.2% | n/c | 1 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 117.05K | n/a | $23.82M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 71.08K | n/a | $14.47M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Adage Capital Partners ✦ | 20.90K | n/a | $4.25M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Millennium Management ✦ | 19.93K | n/a | $4.06M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Marshall Wace ✦ | 1.50K | n/a | $305,265 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Fisher Asset Management ✦ | 1.25K | n/a | $253,908 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,014 holders, 76.41M shares, $19.36B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 3.00K sh · $954,060
Officer, Director · 4.67K sh · $1.50M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology